Harrow (HROW) vs Pacira BioSciences (PCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pacira BioSciences (PCRX) has outperformed Harrow (HROW) over the past year, gaining 6.7% versus a loss of 26.9%. Over five years, HROW leads with a +209.6% price change compared with -52.6% for PCRX. Pacira BioSciences is the larger company by market cap ($1.45 billion vs $1.14 billion), about 1.3 times the size.
On valuation, Pacira BioSciences trades at a lower forward P/E (10.5x vs 11.0x for Harrow).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HROW | PCRX |
|---|---|---|
| Share price | $30.43 | $36.31 |
| Market cap | $1.14B | $1.45B |
| 1-day change | -0.64% | +44.07% |
| YTD return | -37.51% | -2.63% |
| 1-year return | -26.92% | +6.69% |
| 5-year return | +209.61% | -52.63% |
| P/E ratio (TTM) | — | 103.73 |
| Forward P/E | 10.97 | 10.48 |
| EPS (TTM) | $-0.99 | $0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $54.85 | $36.33 |
| 52-week low | $28.54 | $18.80 |
| Distance from 52-week high | -44.53% | -0.07% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +113.64% | -17.06% |
| Average volume | 555.14K | 588.87K |
| Shares outstanding | 37.49M | 39.86M |
| Employees | 373 | 825 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PCRX has outperformed HROW by 33.6 percentage points over the past year.
About Harrow
HROW stock →Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 373 employees
About Pacira BioSciences
PCRX stock →Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 825 employees
HROW vs PCRX FAQ
Which is bigger, Harrow or Pacira BioSciences?
Pacira BioSciences (PCRX) is larger, with a market capitalization of $1.45B compared with $1.14B for Harrow (HROW).
Which stock has performed better over the past year, HROW or PCRX?
PCRX returned +6.69% over the past 12 months, compared with -26.92% for HROW (price return, excluding dividends). Past performance does not predict future results.
Are Harrow and Pacira BioSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.